awmsg logo



decitabine (Dacogen®)


Reference No. 507

Publication date:
22/03/2013


Appraisal information

decitabine (Dacogen®) 50 mg powder for concentrate for solution for injection/infusion


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 18/03/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, decitabine (Dacogen®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia, according to the World Health Organisation classification, who are not candidates for standard induction chemotherapy.
Statement of Advice (SOA)
Download